Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Part of paid clinical trials in Rochester, New York.

Sponsor
University of Rochester
Study ID
NCT05109052
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This trial will assess the safety and tolerability of PXS-5505 incorporating first-line combination therapy Atezolizumab and Bevacizumab in unresectable or metastatic hepatocellular carcinoma. Phase 2 will assess the efficacy of this combination therapy in unresectable or metastatic hepatocellular carcinoma.

Key Dates

Start date
Sep 20, 2022
Status verified
Jul 2023
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Open label safety and tolerability assessment of PXS-5505: (PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] [ Time Frame: 10 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642-

Find similar trials in Rochester, NY

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
University of Rochester· Rochester, NY

Related Studies